Innate Pharma
(NASDAQ:IPHA)
$2.45
0.05[2.08%]
At close: Apr 26
$2.45
0[0.00%]
After Hours: 9:28AM EDT
OverviewNewsEarningsGuidanceDividendsAnalyst RatingsInsider TradesShort Interest

Innate Pharma Stock (NASDAQ:IPHA), Quotes and News Summary

Innate Pharma Stock (NASDAQ: IPHA) stock price, news, charts, stock research, profile.

Open$2.440
Close$2.460
Volume / Avg.6.799K / 9.834K
Day Range2.410 - 2.460
52 Wk Range1.810 - 3.570
Market Cap$198.063M
P/E Ratio-
Dividend Yield-
ExchangeNASDAQ
RSI
50
Short Interest-
Days to Cover7.51

Recent News

Regulatory Hurdle For Innate Pharma's Blood Cancer Studies
The FDA has placed a clinical hold on Innate Pharma SA's (NASDAQ: IPHA) lacutamab Investigational New Drug (IND), leading to a pause in new patient enrollment in ongoing lacutamab trials IPH4102-201 (Phase 2 TELLOMAK) and 102 (Phase 1b PTCL). 
Vandana Singh
Sponsored
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis
Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the clinical stage.
Why Shares of Chinese Companies Are Trading Higher? Here Are 55 Stocks Moving In Tuesday's Mid-Day Session
Gainers Elys Game Technology, Corp. (NASDAQ: ELYS) shares jumped 147% to $0.4312. Elys Game Technology and Cloakbook DC have been granted license to open sportsbook in Washington, D.C.
Lisa Levin
-%

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change
Analyst Trend
1
Nov 23
1
Mar
1
Apr
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
About Innate Pharma
Sector
Health Care
Industry
Biotechnology
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherap...
Show More

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
IPHA
OTLK

FAQ

Q

How do I buy Innate Pharma (IPHA) stock?

A

You can purchase shares of Innate Pharma (NASDAQ: IPHA) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Innate Pharma's (IPHA) competitors?

A

Other companies in Innate Pharma’s space includes: Outlook Therapeutics (NASDAQ:OTLK), Adverum Biotechnologies (NASDAQ:ADVM), bluebird bio (NASDAQ:BLUE), Atossa Therapeutics (NASDAQ:ATOS) and Agenus (NASDAQ:AGEN).

Q

What is the target price for Innate Pharma (IPHA) stock?

A

The latest price target for Innate Pharma (NASDAQ: IPHA) was reported by HC Wainwright & Co. on Thursday, April 11, 2024. The analyst firm set a price target for 11.50 expecting IPHA to rise to within 12 months (a possible 367.48% upside). 5 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Innate Pharma (IPHA)?

A

The stock price for Innate Pharma (NASDAQ: IPHA) is $2.46 last updated April 26, 2024 at 3:40 PM EDT.

Q

Does Innate Pharma (IPHA) pay a dividend?

A

There are no upcoming dividends for Innate Pharma.

Q

When is Innate Pharma (NASDAQ:IPHA) reporting earnings?

A

Innate Pharma’s FY earnings are confirmed for Thursday, March 21, 2024.

Q

Is Innate Pharma (IPHA) going to split?

A

There is no upcoming split for Innate Pharma.

Q

What sector and industry does Innate Pharma (IPHA) operate in?

A

Innate Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch